Capmatinib-Induced Pseudo–Acute Kidney Injury: A Case Report

Arjunmohan Mohan, Sandra M. Herrmann

Research output: Contribution to journalArticlepeer-review


We present a case of pseudo–acute kidney injury (AKI) following capmatinib therapy in an 84-year-old man with combined non–small cell (adenocarcinoma) and small cell lung cancer with MET exon 14–skipping mutation. His past medical history was significant for chronic kidney disease stage 3 with a baseline serum creatinine (Scr) of 1.6 mg/dL rising to 2.44 mg/dL (estimated glomerular filtration rate [GFR] 24 mL/min/1.73 m2) while on capmatinib. Scr improved to 1.84 mg/dL with the cessation of capmatinib but rose again to 2.22 mg/dL upon resumption of therapy. Further investigation with cystatin C and renal iothalamate clearance showed that despite fluctuation in Scr levels, there was not much variation in GFR calculated using these methods. Urinalysis and urinary protein-creatinine ratio were unremarkable. Treatment with capmatinib was continued at reduced dose and a third instance of rise in Scr was observed, followed by a spontaneous return to baseline. Thus, MET inhibitor therapy can result in an asymptomatic rise in Scr, and it must be distinguished from AKI with more accurate non–creatinine-based methods to evaluate GFR. This could spare such patients from invasive diagnostic tests, such as a kidney biopsy, and premature cessation of prognostically important cancer therapies.

Original languageEnglish (US)
Pages (from-to)120-124
Number of pages5
JournalAmerican Journal of Kidney Diseases
Issue number1
StatePublished - Jan 2022


  • AKI diagnosis
  • MET inhibitor
  • Non–small cell lung carcinoma (NSCLC)
  • Scr elevation
  • acute kidney injury (AKI)
  • artifact
  • capmatinib
  • case report
  • laboratory measurement
  • pseudo-AKI
  • renal function
  • serum creatinine (Scr)

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Capmatinib-Induced Pseudo–Acute Kidney Injury: A Case Report'. Together they form a unique fingerprint.

Cite this